Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
36.70
+1.71 (4.89%)
At close: Jun 26, 2026, 4:00 PM EDT
37.32
+0.62 (1.69%)
After-hours: Jun 26, 2026, 7:11 PM EDT

Crinetics Pharmaceuticals Statistics

Total Valuation

CRNX has a market cap or net worth of $3.87 billion. The enterprise value is $2.63 billion.

Market Cap 3.87B
Enterprise Value 2.63B

Important Dates

The next estimated earnings date is Thursday, August 6, 2026, after market close.

Earnings Date Aug 6, 2026
Ex-Dividend Date n/a

Share Statistics

CRNX has 105.44 million shares outstanding. The number of shares has increased by 12.58% in one year.

Current Share Class 105.44M
Shares Outstanding 105.44M
Shares Change (YoY) +12.58%
Shares Change (QoQ) +9.47%
Owned by Insiders (%) 1.44%
Owned by Institutions (%) 110.60%
Float 95.58M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 214.16
Forward PS 45.53
PB Ratio 3.02
P/TBV Ratio 3.02
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 145.34
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 18.60, with a Debt / Equity ratio of 0.04.

Current Ratio 18.60
Quick Ratio 18.25
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -39.17% and return on invested capital (ROIC) is -25.91%.

Return on Equity (ROE) -39.17%
Return on Assets (ROA) -24.69%
Return on Invested Capital (ROIC) -25.91%
Return on Capital Employed (ROCE) -41.03%
Weighted Average Cost of Capital (WACC) 5.50%
Revenue Per Employee $30,419
Profits Per Employee -$835,670
Employee Count 594
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

In the past 12 months, CRNX has paid $180,000 in taxes.

Income Tax 180,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +20.68% in the last 52 weeks. The beta is 0.24, so CRNX's price volatility has been lower than the market average.

Beta (5Y) 0.24
52-Week Price Change +20.68%
50-Day Moving Average 36.86
200-Day Moving Average 41.75
Relative Strength Index (RSI) 54.74
Average Volume (20 Days) 1,297,229

Short Selling Information

The latest short interest is 12.86 million, so 12.19% of the outstanding shares have been sold short.

Short Interest 12.86M
Short Previous Month 12.64M
Short % of Shares Out 12.19%
Short % of Float 13.45%
Short Ratio (days to cover) 13.44

Income Statement

In the last 12 months, CRNX had revenue of $18.07 million and -$496.39 million in losses. Loss per share was -$5.13.

Revenue 18.07M
Gross Profit -339.11M
Operating Income -545.74M
Pretax Income -496.21M
Net Income -496.39M
EBITDA -541.62M
EBIT -545.74M
Loss Per Share -$5.13
Full Income Statement

Balance Sheet

The company has $1.29 billion in cash and $47.86 million in debt, giving a net cash position of $1.24 billion or $11.79 per share.

Cash & Cash Equivalents 1.29B
Total Debt 47.86M
Net Cash 1.24B
Net Cash Per Share $11.79
Equity (Book Value) 1.28B
Book Value Per Share 12.16
Working Capital 1.25B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$414.17 million and capital expenditures -$5.34 million, giving a free cash flow of -$419.52 million.

Operating Cash Flow -414.17M
Capital Expenditures -5.34M
Depreciation & Amortization 4.13M
Net Borrowing n/a
Free Cash Flow -419.52M
FCF Per Share -$3.98
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -3,020.32%
Pretax Margin -2,746.18%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

CRNX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -12.58%
Shareholder Yield -12.58%
Earnings Yield -12.83%
FCF Yield -10.84%

Analyst Forecast

The average price target for CRNX is $83.14, which is 126.54% higher than the current price. The consensus rating is "Strong Buy".

Price Target $83.14
Price Target Difference 126.54%
Analyst Consensus Strong Buy
Analyst Count 16
Revenue Growth Forecast (3Y) 279.45%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

CRNX has an Altman Z-Score of 16.5 and a Piotroski F-Score of 3.

Altman Z-Score 16.5
Piotroski F-Score 3